These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 27390130)

  • 21. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
    Baraliakos X; Kivitz AJ; Deodhar AA; Braun J; Wei JC; Delicha EM; Talloczy Z; Porter B;
    Clin Exp Rheumatol; 2018; 36(1):50-55. PubMed ID: 28516874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
    Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
    Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
    Sieper J; Deodhar A; Marzo-Ortega H; Aelion JA; Blanco R; Jui-Cheng T; Andersson M; Porter B; Richards HB;
    Ann Rheum Dis; 2017 Mar; 76(3):571-592. PubMed ID: 27582421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
    Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
    J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J; McHugh N; Singh A; Wajdula JS; Sato R
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
    Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
    N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
    Madsen OR
    Rheumatol Int; 2018 Mar; 38(3):425-432. PubMed ID: 29299630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.
    Dubreuil M; Navarro-Compán V; Boonen A; Gaffney K; Gensler LS; de la Loge C; Vaux T; Fleurinck C; Massow U; Taieb V; Mørup MF; Deodhar A; Rudwaleit M
    RMD Open; 2024 Jun; 10(2):. PubMed ID: 38834351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial.
    Gonzalez-Lopez L; Garcia-Gonzalez A; Vazquez-Del-Mercado M; Muñoz-Valle JF; Gamez-Nava JI
    J Rheumatol; 2004 Aug; 31(8):1568-74. PubMed ID: 15290737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice.
    Haibel H; Song IH; Rudwaleit M; Listing J; Hildemann S; Sieper J
    Clin Exp Rheumatol; 2008; 26(2):247-52. PubMed ID: 18565245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
    Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
    Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
    Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.
    Deodhar A; Conaghan PG; Kvien TK; Strand V; Sherif B; Porter B; Jugl SM; Gandhi KK;
    Clin Exp Rheumatol; 2019; 37(2):260-269. PubMed ID: 30148436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of ultrasound treatment applied with exercise therapy on patients with ankylosing spondylitis: a double-blind, randomized, placebo-controlled trial.
    Şilte Karamanlioğlu D; Aktas I; Ozkan FU; Kaysin M; Girgin N
    Rheumatol Int; 2016 May; 36(5):653-61. PubMed ID: 26923690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12].
    Haibel H; Niewerth M; Brandt J; Rudwaleit M; Listing J; Sieper J; Braun J
    Z Rheumatol; 2004 Oct; 63(5):393-401. PubMed ID: 15517300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.